insert the company's "EsophyX"
through the mouth into the
upper part of the esophagus,
using visual guidance from an
endoscope. Instead of a 360°
wrap, it uses fasteners to create
a 270° valve that's 2 to 3 cen-
timeters long. Ideally, it corrects
the anatomic defect that can
cause GERD, recreating the
body's natural anti-reflux barrier.
There's considerable data to
support the FDA-approved pro-
cedure's efficacy, including sev-
eral years of follow-up data, but
most studies have looked prima-
rily at patients who didn't have
severe erosive esophagitis or
large hiatal hernias. Those can
be complicating factors. Still, it's
been shown to work on both
heartburn and regurgitation
symptoms as well. Additionally,
patients with refractory GERD
— that is, those who continue to
have symptoms after being treat-
ed with twice daily PPIs — also
appear to respond positively to
the treatment.
The procedure requires some
A U G U S T 2 0 1 6 • O U T PA T I E N TS U R G E R Y. N E T • 8 3
Dr Jacobs
Treating GERD
su erers for 18 years
With the strongest record of
clinical success, proven in multiple
randomized clinical trials, you can
be certain the TIF
®
procedure with
the EsophyX
®
device will help your
patients get back to living.
www.EndoGastricSolutions.com
The TIF® procedure is designed to treat GERD symptoms with the
EsophyX® technology—a cleared device. Results may vary; visit
GERDHelp.com for clinical data. EndoGastric Solutions, Inc. is the
manufacturer and owner of these trademarks: TIF, EsophyX and
SerosaFuse. ©2016 All rights reserved. NP02456-01C
GERD has taken a lot
from your patients.
Help them get back
to themselves.
Project1_Layout 1 7/14/16 7:36 AM Page 1
